D-Index & Metrics Best Publications
Research.com 2023 Best Scientist Award Badge
Medicine
USA
2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 244 Citations 281,641 4,544 World Ranking 23 National Ranking 18
Best Scientists D-index 244 Citations 281,729 4,557 World Ranking 35 National Ranking 26

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Scientist Award

2023 - Research.com Medicine in United States Leader Award

2022 - Research.com Best Scientist Award

2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study Hagop M. Kantarjian is best known for:

  • Chemotherapy
  • Cancer
  • Leukemia

His research on Chronic lymphocytic leukemia, Cytarabine and Chronic myelogenous leukemia is centered around Leukemia. He merges many fields, such as Chronic lymphocytic leukemia and Fludarabine, in his writings. He conducted interdisciplinary study in his works that combined Cytarabine and Chemotherapy. He conducts interdisciplinary study in the fields of Chemotherapy and Cyclophosphamide through his works. His multidisciplinary approach integrates Cyclophosphamide and Fludarabine in his work. The research on Nilotinib, Imatinib mesylate and Dasatinib is part of his Imatinib project. His Internal medicine study typically links adjacent topics like Clinical trial. He carries out multidisciplinary research, doing studies in Gastroenterology and Oncology. In his study, Hagop M. Kantarjian carries out multidisciplinary Oncology and Gastroenterology research.

His most cited work include:

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (869 citations)
  • Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy (410 citations)
  • Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (357 citations)

What are the main themes of his work throughout his whole career to date

As part of his inquiry into Chronic myelogenous leukemia and Chronic lymphocytic leukemia, Hagop M. Kantarjian is doing Leukemia research. Hagop M. Kantarjian carries out multidisciplinary research, doing studies in Chronic lymphocytic leukemia and Leukemia. He integrates many fields, such as Imatinib and engineering, in his works. As part of his studies on Internal medicine, Hagop M. Kantarjian often connects relevant subjects like Adverse effect. Hagop M. Kantarjian undertakes interdisciplinary study in the fields of Oncology and Gastroenterology through his works. He undertakes interdisciplinary study in the fields of Gastroenterology and Oncology through his works. His work on Dasatinib expands to the thematically related Myeloid leukemia. By researching both Gene and Biochemistry, he produces research that crosses academic boundaries. He integrates Biochemistry and Gene in his studies.

Hagop M. Kantarjian most often published in these fields:

  • Internal medicine (89.19%)
  • Oncology (55.41%)
  • Gastroenterology (50.68%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)

6582 Citations

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)

5334 Citations

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4398 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

4139 Citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)

3441 Citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2683 Citations

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)

2611 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2302 Citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)

2074 Citations

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)

2071 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hagop M. Kantarjian

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 330

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 301

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 297

Pierre Fenaux

Pierre Fenaux

Université Paris Cité

Publications: 282

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 278

John C. Byrd

John C. Byrd

University of Cincinnati

Publications: 274

Brian J. Druker

Brian J. Druker

Oregon Health & Science University

Publications: 255

Peter Valent

Peter Valent

Medical University of Vienna

Publications: 247

Elihu H. Estey

Elihu H. Estey

University of Washington

Publications: 245

Richard Stone

Richard Stone

Harvard University

Publications: 243

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 239

Ross L. Levine

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Publications: 237

Ruben A. Mesa

Ruben A. Mesa

The University of Texas Health Science Center at San Antonio

Publications: 230

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 225

Timothy P. Hughes

Timothy P. Hughes

South Australian Health and Medical Research Institute

Publications: 222

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 219

Trending Scientists

Stephen J. Page

Stephen J. Page

University of Hertfordshire

Kevin Lai

Kevin Lai

Amazon (United States)

Chungu Xia

Chungu Xia

Chinese Academy of Sciences

Paul D. Prenzler

Paul D. Prenzler

Charles Sturt University

Per-Ola Norrby

Per-Ola Norrby

AstraZeneca (United Kingdom)

Michael B. Stadler

Michael B. Stadler

Friedrich Miescher Institute

John J. Burke

John J. Burke

Agricultural Research Service

Patricia M. Schulte

Patricia M. Schulte

University of British Columbia

Malcolm K. Jones

Malcolm K. Jones

University of Queensland

Shijie Zhong

Shijie Zhong

University of Colorado Boulder

Johannes Schneider

Johannes Schneider

Max Planck Institute for Chemistry

Jamie L. Rhudy

Jamie L. Rhudy

University of Tulsa

Maria T. Abreu

Maria T. Abreu

University of Miami

Eric C. Holland

Eric C. Holland

Fred Hutchinson Cancer Research Center

Rogier M. Bertina

Rogier M. Bertina

Leiden University Medical Center

Something went wrong. Please try again later.